Gain-of-Function Variant TRPC6 A404V Is Associated With Doxorubicin-Related Cardiomyopathy
Circulation: Genomic and Precision Medicine · 2026
DOI: 10.1161/circgen.125.005334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation: Genomic and Precision Medicine, 2026. Verfasst von Ying Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (Y.W., X.S., H.-C.L., T.L.). Hauptthemen laut MEDLINE: Doxorubicin, TRPC6 Cation Channel, Cardiomyopathies, Gain of Function Mutation. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: TRPC6 (transient receptor potential canonical 6) channels, encoded by the TRPC6 gene, are widely expressed in cardiomyocytes and play a critical role in maintaining intracellular Ca 2 + homeostasis. Variants in TRPC6 are associated with chemotherapy-related cardiomyopathy. Specifically, the TRPC6 A404V polymorphism, with a minor (404 V) allele frequency of 12% in the general population, has been identified in patients undergoing anthracycline therapy. However, the underlying mechanisms remain largely unexplored. METHODS: Using patch-clamp recordings, Ca 2 + imaging, computational analysis, and molecular biology techniques, we assessed the effects of doxorubicin and its metabolite, doxorubicinol, on regulating TRPC6 alanine (A) at position 404 replaced by valine (V; A404V) channel expression and function in a heterologous expression system and native cardiac cells. RESULTS: Both additive and recessive models demonstrated a significant association between the TRPC6 A404V variant and doxorubicin-related cardiomyopathy. The TRPC6 A404V channel exhibited higher membrane expression levels compared with the wild type (WT) control. Patch-clamp recordings showed that both TRPC6 WT and A404V channels remained mostly inactive at baseline. Application of 50 μmol/L 1-oleoyl acetyl-sn-glycerol (OAG), a TRPC6 activator, significantly increased the inward- and outward-current densities of WT and A404V channels. Furthermore, a 24-hour treatment with 0.5 μmol/L doxorubicin enhanced TRPC6 mRNA expression and potentiated the OAG effects on both WT and A404V channels, with a more pronounced response in A404V channels. Treatment with 0.5 μmol/L doxorubicinol had no effect on OAG-induced current densities in either WT or A404V channels. Doxorubicin effects on intracellular Ca 2 + levels were confirmed by Ca 2 + imaging in native cardiac cells. Computational modeling revealed that the A404V mutation induces a conformational change in the OAG-binding pocket, enhancing its interaction with OAG in the A404V protein compared with the WT control. CONCLUSIONS: The TRPC6 A404V is a gain-of-function variant that exhibits enhanced activity in the presence of doxorubicin. Therefore, the TRPC6 A404V variant represents a risk factor for anthracycline-induced cardiotoxicity in patients with cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (Y.W., X.S., H.-C.L., T.L.).
- Department of Cardiology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Jiangsu Province, P.R. China (Y.W., R.-X.W.).
- Department of Quantitative Health Sciences (J.S.R.), Mayo Clinic, Jacksonville, FL.
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL (N.N.).
ORCID-Profile: Ying Wu, Xiaojing Sun, Joseph S Reddy, Hon-Chi Lee, Nadine Norton, Tong Lu
Förderung
- NHLBI NIH HHS
Zitieren
APA
Wu, Y., Sun, X., Wang, R. X., Reddy, J. S., Lee, H. C., Norton, N., & Lu, T. (2026). Gain-of-Function Variant TRPC6 A404V Is Associated With Doxorubicin-Related Cardiomyopathy. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.125.005334
Vancouver
Wu Y, Sun X, Wang RX, Reddy JS, Lee HC, Norton N, et al. Gain-of-Function Variant TRPC6 A404V Is Associated With Doxorubicin-Related Cardiomyopathy. Circulation: Genomic and Precision Medicine. 2026. doi:10.1161/circgen.125.005334
BibTeX
@article{Wu2026,
author = {Wu, Ying and Sun, Xiaojing and Wang, Ru-Xing and Reddy, Joseph S and Lee, Hon-Chi and Norton, Nadine and Lu, Tong},
title = {Gain-of-Function Variant TRPC6 A404V Is Associated With Doxorubicin-Related Cardiomyopathy},
journal = {Circulation: Genomic and Precision Medicine},
year = {2026},
doi = {10.1161/circgen.125.005334}
}
EUVIMED